Flexicare Lanka – a fully owned subsidiary of Flexicare Group, U.K. – has set up a state-of-the-art modern manufacturing facility in Bandaragama with a total investment of over USD 15 Million. This is the first time in Sri Lanka’s history of manufacturing that such a state-of-the-art medical device production plant begins its operations in the country.
With over 90% of the production intended for exports, Sri Lanka is placed on the global medical consumable devices production map for the first time. Flexicare Lanka will be employing over 600 people as part of its first phase, as it gears up production from its current workforce of 150 with plans for a second expansion in due course.
The facility in Bandaragama began construction in 2019 and is now fully operational. In an event planned to mark this historic occasion, the site will be officially unveiled by the Finance Minister of The Democratic Socialist Republic of Sri Lanka, Honourable Basil Rajapakse on 17th November 2021.
“Flexicare has invested over $15m USD into this project to support the growing demand within the region for high quality medical products. Not only the first medical devices manufacturer in Sri Lanka, but working alongside with the BOI and government agencies, we are the first entity to have terminal ethylene oxide sterilisation technology introduced here which allows us to produce sterile products for our clinical environments,” states Ghassem Poormand, Chairman of Flexicare Group.
Additionally, Hash Poormand – Managing Director of Flexicare Group states: “With the advent of the COVID-19 pandemic, there has been no more an important time that life sustaining and lifesaving products are made available and accessible for our patients. Flexicare Lanka has been instrumental in ensuring that urgent medical devices were delivered across the world.”
Flexicare is a privately owned leading designer, manufacturer and supplier of medical devices backed by over 30 years of experience in the healthcare sector. Headquartered in the UK, Flexicare has expanded its international reach to over 110 countries, supported by wholly owned subsidiaries and scientific offices in the USA, South America, Netherlands, Germany, Italy, Turkey, Jordan, Egypt, India, Sri Lanka, Malaysia, Korea, China, Japan and Australia.
With state of the art, purpose-built manufacturing facilities in key markets, the company has continued to expand its operations and capabilities that serve to provide a vertically integrated business model that has full control over the production and supply chain of its anaesthesia and respiratory portfolio.
For further information, please visit www.flexicare.com.
